SVB Securities analyst Thomas Smith reiterated a Buy rating on Connect Biopharma Holdings (CNTB – Research Report) on July 12. The company’s shares closed last Wednesday at $0.92, close to its 52-week low of $0.56.
According to TipRanks.com, Smith has 0 stars on 0-5 stars ranking scale with an average return of -26.3% and a 20.7% success rate. Smith covers the Healthcare sector, focusing on stocks such as Madrigal Pharmaceuticals, Prometheus Biosciences, and Eledon Pharmaceuticals.
Connect Biopharma Holdings has an analyst consensus of Moderate Buy, with a price target consensus of $3.25.
See Insiders’ Hot Stocks on TipRanks >>
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Connect Biopharma Holdings Ltd is a clinical-stage company focused on the discovery and development of next-generation immune modulators for the treatment of serious autoimmune diseases and inflammation. It has leveraged its expertise in the biology of T cell modulation to build a portfolio of drug candidates consisting of small molecules and antibodies targeting critical pathways of inflammation. Its pipeline includes CBP-201, CBP-307, CBP-174, and CBP-233.
Read More on CNTB:
- Linde (LIN): New Buy Recommendation for This Materials Giant
- UBS Thinks LANXESS’s Stock is Going to Recover
- SVB Securities Keeps a Hold Rating on scPharmaceuticals (SCPH)
- SVB Securities Sticks to Their Buy Rating for Aldeyra Therapeutics (ALDX)
- Mizuho Securities Maintains Their Buy Rating on Williams Co (WMB)
